Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia

American Journal of Psychiatry

Volumn 158, Issue 9, 2001, Pages 1393-1399

  Smith, R E ^a   Haroutunian, V ^a   Davis, K L ^a   Meador Woodruff, J H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA PROBE; SCHIZOPHRENIA; THALAMUS NUCLEUS;

AGED; AMINO ACID TRANSPORT SYSTEM X-AG; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IN SITU HYBRIDIZATION; MALE; MEMBRANE GLYCOPROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; RNA, MESSENGER; SCHIZOPHRENIA; SYMPORTERS; THALAMIC NUCLEI; THALAMUS; TRANSCRIPTION, GENETIC;

EID: 0034849588     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.9.1393     Document Type: Article

References (68)

1. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging
2. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics
3. The thalamus and the schizophrenia phenotype: Failure to replicate reduced volume
4. PET and MRI of the thalamus in never-medicated patients with schizophrenia
5. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging
6. Partial volume decrease of the thalamus in relatives of patients with schizophrenia
7. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients
8. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia
9. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum
10. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry
11. "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry?
12. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia
13. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
14. Recent advances in the phencyclidine model of schizophrenia
15. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
16. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
17. Model psychoses and schizophrenia
18. Effect of phencyclidine in chronic schizophrenics
19. Phencyclidine selectively blocks a spinal action of N-methyl-D-aspartate in mice
20. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
21. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
22. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus
23. Expression patterns and regulation of glutamate transporters in the developing and adult nervous system
24. Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family
25. Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter
26. A reentrant loop domain in the glutamate carrier EAAT1 participates in substrate binding and translocation
27. Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: Involvement of high affinity transporter mechanisms
28. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance
29. EAAT4, a glutamate transporter with properties of a chloride channel, is predominantly localized in Purkinje cell dendrites, and forms parasagittal compartments in rat cerebellum
30. Distribution of glutamate transporter subtypes during human brain development
31. Expression of the glial glutamate transporter EAAT2 in the human CNS: An immunohistochemical study
32. Differential expression of two glial glutamate transporters in the rat brain: Quantitative and immunocytochemical observations
33. Localization of neuronal and glial glutamate transporters
34. Glutamate transporter protein subtypes are expressed differentially during rat CNS development
35. EAAT4 is a post-synaptic glutamate transporter at Purkinje cell synapses
36. Changes in expression and distribution of the glutamate transporter EAAT4 in developing mouse Purkinje cells
37. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate
38. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1
39. Inducible expression and pharmacology of the human excitatory amino acid transporter 2 subtype of L-glutamate transporter
40. The family of sodium-dependent glutamate transporters: A focus on the GLT-1/EAAT2 subtype
41. Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice
42. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals
43. The EAAT2 (GLT-1) gene in motor neuron disease: Absence of mutations in amyotrophic lateral sclerosis and a point mutation in patients with hereditary spastic paraplegia
44. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
45. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: An immunohistochemical study
46. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - An in situ hybridization study
47. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia
48. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex
49. Venom phospholipase A2-induced impairment of glutamate uptake: An indirect and nonselective effect related to phospholipid hydrolysis
50. Cytokine effects on glutamate uptake by human astrocytes
51. Reversible activation of glutamate transport in rat brain glia by protein kinase C and an okadaic acid-sensitive phosphoprotein phosphatase
52. Lithium acutely inhibits and chronically upregulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex
53. Wnt signaling induces GLT-1 expression in rat C6 glioma cells
54. The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms
55. 3H]arachidonic acid release in cerebellar granule cells
56. 3H-glutamate uptake with different potencies in rodent central nervous system regions expressing different transporter subtypes
57. NMDA receptor-mediated arachidonic acid release in neurons: Role in signal transduction and pathological aspects
58. Activation of N-methyl-D-aspartate-sensitive glutamate receptors stimulates arachidonic acid release in primary cultures of cerebellar granule cells
59. N-Methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells
60. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms
61. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders
62. NMDA receptors activate the arachidonic acid cascade system in striatal neurons
63. Dorsolateral prefrontal cortex pathology in schizophrenia: Excitatory amino acid transporters 1 and 2
64. Excitatory amino acid transporter 3 mRNA and protein in DLPFC of schizophrenia
65. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum
66. Chronic haloperidol treatment impairs glutamate transport in the rat striatum
67. Expression and function of glutamate transporter GLT-1 are downregulated by the antipsychotic clozapine